{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:29:02Z","timestamp":1784762942508,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Value\u2010based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value\u2010based pricing to reference cost\u2010effectiveness thresholds (\u03bb) on individual and population\u2010level health benefits remains uncharacterized. The current study examined the potential benefits of value\u2010based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology drugs, if funding occurred at manufacturer\u2010submitted price without value\u2010based pricing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pan\u2010Canadian Oncology Drug Review (pCODR) submissions were reviewed to identify eligible drug indications from which final economic guidance panel reports were reviewed for incremental costs (\u0394C) and quality\u2010adjusted life\u2010years (\u0394QALY) from manufacturer\u2010submitted, pCODR lower\u2010limit (pCODR\u2010LL) and upper\u2010limit (pCODR\u2010UL) re\u2010analyzed estimates. Annual number of cases in Ontario for each drug indication was obtained from population databases. Annual QALY gain per drug indication was determined by (\u0394QALY\u00a0\u00d7\u00a0cases). Population QALY gain\/loss in the absence of value\u2010based pricing to reference \u03bb was estimated by the INHB: (INHB\u00a0=\u00a0[\u0394QALY\u00a0\u2212\u00a0(\u0394C\/\u03bb)]\u00a0\u00d7\u00a0cases).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 34 drug indications (4629 cases) were identified. Annual gain in QALYs for the funded drug indications using manufacturer, pCODR\u2010LL, and pCODR\u2010UL estimates was 1851, 1617, and 1301, respectively. At a \u03bb $100\u00a0000\/QALY, funding in the absence of value\u2010based pricing resulted in loss of 2311, 2519, and 2604 QALYs. This would result in a provincial net annual loss of 460, 902, and 1303 QALYs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite an annual gain in QALY per funded drug indication, a net loss in QALY for the province, in the absence of value\u2010based pricing, was demonstrated. Supportive evidence exists for value\u2010based pricing toward the promotion of health benefits for the greater population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.2694","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:18:27Z","timestamp":1573517907000},"page":"94-103","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Value\u2010based pricing: Toward achieving a balance between individual and population gains in health benefits"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-3843","authenticated-orcid":false,"given":"Ambica","family":"Parmar","sequence":"first","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Jiao","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-4649","authenticated-orcid":false,"given":"Ronak","family":"Saluja","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3057","authenticated-orcid":false,"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre Toronto ON Canada"},{"name":"Sunnybrook Research Institute Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20170144"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1183"},{"key":"e_1_2_7_4_1","unstructured":"National Cancer Institute.Financial burden of cancer care.2019. Retrieved fromhttps:\/\/progressreport.cancer.gov\/after\/."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0373"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.17.00058"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.03.011"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4871"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.109-5538"},{"key":"e_1_2_7_10_1","volume-title":"Value\u2010based pricing of pharmaceuticals in Canada: opportunities to expand the role of health technology assessment? Paper 5","author":"Husereau D","year":"2011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1409"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czl018"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1481"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2018.1447828"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2006.00509.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1050(200006)9:4<327::AID-HEC517>3.0.CO;2-S"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311816"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.1.1.37"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0566-5"},{"key":"e_1_2_7_21_1","unstructured":"Statistics Canada.Table 17\u201310\u2010009\u201001 population estimates quarterly. Retrieved from:https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pxml:id=1710000901#timeframe."},{"key":"e_1_2_7_22_1","unstructured":"Statistics Canada.Consumer Price Index CANSIM (database) Statistics Canada [serial online].2018. Retrieved from:https:\/\/www150.statcan.gc.ca\/."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70273-5"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx110"},{"key":"e_1_2_7_25_1","unstructured":"ClaxtonK.Pharmaceutical pricing: early access the Cancer Drugs Fund and the Role of NICE. Policy and research briefing. Centre for Health Economics University of York.2016. Retrieved from:http:\/\/eprints.whiterose.ac.uk\/103088\/1\/Drug_prices.pdf."},{"key":"e_1_2_7_26_1","unstructured":"House of Commons Committee of Public Accounts.Cancer Drugs Fund\u201420threport. House of Commons.2016. Retrieved from:https:\/\/publications.parliament.uk\/pa\/cm201516\/cmselect\/cmpubacc\/583\/583.pdf."},{"key":"e_1_2_7_27_1","unstructured":"Government of Quebec.Institut national d'excellence en sant\u00e9 et en services sociaux.2018. Retrieved from:https:\/\/www.inesss.qc.ca\/en\/about-us\/about-the-institut.html."},{"key":"e_1_2_7_28_1","unstructured":"Canadian Agency for Drugs and Technologies and Health.Pan\u2010Canadian oncology drug reviews.2019. Retrieved from:https:\/\/www.cadth.ca\/pcodr\/."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.2673"},{"key":"e_1_2_7_30_1","unstructured":"The Council of the Federation Canada's Premiers.The pan\u2010Canadian Pharmaceutical Alliance.2019. Retrieved from:http:\/\/www.canadaspremiers.ca\/pan-canadianpharmaceutical-alliance\/."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11237"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.27.1.33"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2148"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001351"},{"key":"e_1_2_7_35_1","unstructured":"Centers for Medicare and Medicaid Services.National health expenditure data.2019. Retrieved from:https:\/\/www.cms.gov\/research-statistics-data-and-systems\/statistics-trends-and-reports\/nationalhealthexpenddata\/nationalhealthaccountsprojected.html."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0489-1"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.26.6.1666"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-S1-24"},{"key":"e_1_2_7_39_1","first-page":"1","article-title":"Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population","volume":"10","author":"Lizan L","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.15.164418"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.14.138206"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0606-1"},{"key":"e_1_2_7_43_1","unstructured":"Institute for Clinical and Economic Review.Overview of the ICER assessment framework and update for 2017\u20132019. 2017\u20102019. Retrieved from:http:\/\/icer-review.org\/wpcontent\/uploads\/2017\/06\/ICER-value-assessment-framework-Updated-050818.pdf."},{"key":"e_1_2_7_44_1","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations","volume":"146","author":"Laupacis A","year":"1992","journal-title":"CMAJ"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta19140"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.017"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0162-x"},{"key":"e_1_2_7_48_1","volume-title":"Using cost\u2010effectiveness thresholds to determine value for money in low\u2010 and middle\u2010income country healthcare systems: are current international norms fit for purpose? CHE Research Paper no. 98","author":"Revill P","year":"2014"},{"key":"e_1_2_7_49_1","unstructured":"Government of Canada.PMPRB Steering Committee on the modernization of price review guidelines.2019. Retrieved from:http:\/\/www.pmprb-cepmb.gc.ca\/CMFiles\/Consultations\/new_guidelines\/steering-committee-final-report-en.pdf."},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.292"},{"key":"e_1_2_7_51_1","unstructured":"National Institute for Health and Care Excellence.Guide to the methods of technology appraisal.2013. Retrieved from:https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf."},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.3033"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2694","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2694","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:21:55Z","timestamp":1694114515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/cam4.2694"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2694","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"2019-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}